A Novel Approach in the Treatment of Renal Cell Carcinoma

A Novel Approach in the Treatment of Renal Cell Carcinoma
PropertyValue
Title:A Novel Approach in the Treatment of Renal Cell Carcinoma
Author/Abstract:
Victor D. Espino, MD and Jose Dante P. Dator, MD

Department of Urology, National Kidney and Transplant Institutetute


Renal Cell Carcinoma (RCCA) is the most common type of kidney cancer in adults. Radical nephrectomy is still the gold standard in the treatment of this disease. At present, there is no established adjuvant treatment in preventing relapses and metastatic spread of RCCA. However, current trials with adjuvant autologous vaccine using dendritic cells have reported successful prevention of relapses and improved survival rates among those diagnosed with early stage of RCCA. Last December 2005, a 72 year old male was diagnosed with bilateral renal masses. RCCA was confirmed after surgery when the patient underwent bilateral partial nephrectomies. Thereafter, we were able to isolate a pure cell culture of renal cell carcinoma and fused these with the dendritic cells harvested from the patient producing the autologous vaccine, which was later administered. To date, this is the first case of developing dendritic cell vaccine to treat renal cell carcinoma in the Philippines.

Key words: renal cell carcinoma, radical nephrectomy, autologous vaccine, dendritic cells
Filesize: 303.59 kB
Filetype:pdf (Mime Type: application/pdf)